Home » Newsletters » BioWorld Science

BioWorld Science

June 3, 2009

View Archived Issues

AAV 8-mediated gene therapy rescues lethal murine model of methylmalonic acidemia

Pharmacokinetics of aerosolized amikacin assessed in patients with impaired renal function

Cinacalcet may be beneficial in patients with post-renal transplant hyperparathyroidism

AstraZeneca discloses discovery of novel FGFR inhibitors as oncolytic agents

Sanofi-aventis claims novel c-Met kinase inhibitors for cancer treatment

Novel 11beta-hydroxysteroid dehydrogenase type 1 inhibitors claimed by AstraZeneca as antidiabetics

GlaxoSmithKline presents prostanoid EP4 receptor agonists for the treatment of pain

H7N3 live attenuated virus vaccine found safe and immunogenic in phase I trial in healthy subjects

Oncolytic herpes simplex virus shows activity in metastatic colorectal cancer

Telomelysin well tolerated in phase I trial in advanced cancer patients

Novartis reviews developments in first quarter

Sanofi-aventis and Exelixis sign agreements for XL-147, XL-765 and PI3K inhibitors

Proteon completes second closing of financing and receives orphan drug status

Pfizer discontinues phase III trial of sunitinib in advanced breast cancer

Inspire develops novel ROCK inhibitors as oral and inhaled bronchodilators

BioLineRx reports positive results from phase I/II clinical trial of BL-1040 in MI

Concert and GlaxoSmithKline collaborate on deuterium-modified drugs

CHMP recommends approval of Afinitor for patients with advanced kidney cancer

ODAC makes favorable recommendation for Arzerra in CLL

ARCA biopharma receives FDA complete response letter for Gencaro

FDA accepts Stedesa NDA filing for review

FDA approves Reclast single infusion to prevent osteoporosis in postmenopausal women

AMRI selects MCH1 receptor antagonist for advanced preclinical testing in obesity

Can-Fite completes patient enrollment in phase II trial of CF-101 in psoriasis

FDA grants orphan drug designation to NeurogesX's Qutenza for PHN

Active Biotech completes patient enrollment in Anyara phase III clinical trial

Theratechnologies files NDA with FDA for tesamorelin for HIV patients with lipodystrophy

Pharmacokinetics, safety suggest HPN-100 is appropriate for hepatic encephalopathy